GT Biopharma Inc (GTBP)

US · Healthcare · Biotechnology

$4.42-2.64%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Net profit

$-4.5M

EPS

$-0.12

EPS estimate

$-0.08

EPS came in at -0.12 against a street estimate of -0.08 — a miss of 50.0%.

Market cap

$9.4M

Forward P/E

17.3

P/B

2.67

Book value

$2.00

EPS (TTM)

$-147.50

52-week high

$28.75

52-week low

$4.21

50-day MA

$6.56

200-day MA

$9.48

Beta

0.83

Analysts rate GT Biopharma Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $75.00.

Insiders

10.35%

Institutions

8.15%

Fund	Stake
Vanguard Capital Management, LLC	0.73%
Geode Capital Management, LLC	0.52%
Vanguard Fiduciary Trust Co	0.44%
HRT FINANCIAL LLC	0.21%
Everhart Financial Group, Inc.	0.19%
SRS Capital Advisors Inc	0.18%
Opal Wealth Advisors, LLC	0.16%
Northern Trust Corp	0.15%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for GT Biopharma Inc — free to start.

Data updated 2026-11-07.